TY - JOUR
T1 - Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma
T2 - Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy
AU - Perales, Miguel Angel
AU - Anderson, Larry D.
AU - Jain, Tania
AU - Kenderian, Saad S.
AU - Oluwole, Olalekan O.
AU - Shah, Gunjan L.
AU - Svoboda, Jakub
AU - Hamadani, Mehdi
N1 - Publisher Copyright:
© 2022 The American Society for Transplantation and Cellular Therapy
PY - 2022/9
Y1 - 2022/9
N2 - Since 2017, 3 CD19-directed chimeric antigen receptor (CAR) T cell therapies—axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel—have been approved for relapsed/refractory aggressive diffuse large B cell lymphoma after 2 lines of therapy. Recently, 3 prospective phase 3 randomized clinical trials were conducted to define the optimal second-line treatment by comparing each of the CAR T cell products to the current standard of care: ZUMA-7 for axicabtagene ciloleucel, BELINDA for tisagenlecleucel, and TRANSFORM for lisocabtagene maraleucel. These 3 studies, although largely addressing the same question, had different outcomes, with ZUMA-7 and TRANSFORM demonstrating significant improvement with CD19 CAR T cells in second-line therapy compared with standard of care but BELINDA not showing any benefit. The US Food and Drug Administration has now approved axicabtagene ciloleucel and lisocabtagene maraleucel for LBCL that is refractory to first-line chemoimmunotherapy or relapse occurring within 12 months of first-line chemoimmunotherapy. Following the reporting of these practice changing studies, here a group of experts convened by the American Society for Transplantation and Cellular Therapy provides a comprehensive review of the 3 studies, emphasizing potential differences, and shares perspectives on what these results mean to clinical practice in this new era of treatment of B cell lymphomas.
AB - Since 2017, 3 CD19-directed chimeric antigen receptor (CAR) T cell therapies—axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel—have been approved for relapsed/refractory aggressive diffuse large B cell lymphoma after 2 lines of therapy. Recently, 3 prospective phase 3 randomized clinical trials were conducted to define the optimal second-line treatment by comparing each of the CAR T cell products to the current standard of care: ZUMA-7 for axicabtagene ciloleucel, BELINDA for tisagenlecleucel, and TRANSFORM for lisocabtagene maraleucel. These 3 studies, although largely addressing the same question, had different outcomes, with ZUMA-7 and TRANSFORM demonstrating significant improvement with CD19 CAR T cells in second-line therapy compared with standard of care but BELINDA not showing any benefit. The US Food and Drug Administration has now approved axicabtagene ciloleucel and lisocabtagene maraleucel for LBCL that is refractory to first-line chemoimmunotherapy or relapse occurring within 12 months of first-line chemoimmunotherapy. Following the reporting of these practice changing studies, here a group of experts convened by the American Society for Transplantation and Cellular Therapy provides a comprehensive review of the 3 studies, emphasizing potential differences, and shares perspectives on what these results mean to clinical practice in this new era of treatment of B cell lymphomas.
KW - Autologous transplant
KW - CRS
KW - Cellular therapy
KW - Chimeric antigen receptor (CAR) T cells
KW - ICANS
KW - Lymphoma
UR - http://www.scopus.com/inward/record.url?scp=85135360795&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135360795&partnerID=8YFLogxK
U2 - 10.1016/j.jtct.2022.06.019
DO - 10.1016/j.jtct.2022.06.019
M3 - Article
C2 - 35768052
AN - SCOPUS:85135360795
SN - 2666-6367
VL - 28
SP - 546
EP - 559
JO - Transplantation and Cellular Therapy
JF - Transplantation and Cellular Therapy
IS - 9
ER -